IL129298A0 - PDE iv inhibiting 2-cyanoiminoimidazole derivatives - Google Patents

PDE iv inhibiting 2-cyanoiminoimidazole derivatives

Info

Publication number
IL129298A0
IL129298A0 IL12929897A IL12929897A IL129298A0 IL 129298 A0 IL129298 A0 IL 129298A0 IL 12929897 A IL12929897 A IL 12929897A IL 12929897 A IL12929897 A IL 12929897A IL 129298 A0 IL129298 A0 IL 129298A0
Authority
IL
Israel
Prior art keywords
pde
inhibiting
cyanoiminoimidazole
derivatives
cyanoiminoimidazole derivatives
Prior art date
Application number
IL12929897A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL129298A0 publication Critical patent/IL129298A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/48Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL12929897A 1996-10-02 1997-09-24 PDE iv inhibiting 2-cyanoiminoimidazole derivatives IL129298A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96202749 1996-10-02
PCT/EP1997/005322 WO1998014432A1 (en) 1996-10-02 1997-09-24 Pde iv inhibiting 2-cyanoiminoimidazole derivatives

Publications (1)

Publication Number Publication Date
IL129298A0 true IL129298A0 (en) 2000-02-17

Family

ID=8224456

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12929897A IL129298A0 (en) 1996-10-02 1997-09-24 PDE iv inhibiting 2-cyanoiminoimidazole derivatives
IL129298A IL129298A (en) 1996-10-02 1999-03-31 History 2 - Cyanoiminoindole inhibiting PDE IV

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL129298A IL129298A (en) 1996-10-02 1999-03-31 History 2 - Cyanoiminoindole inhibiting PDE IV

Country Status (30)

Country Link
US (1) US6051718A (pl)
EP (1) EP0934280B1 (pl)
JP (1) JP3068208B2 (pl)
KR (1) KR100520002B1 (pl)
CN (1) CN1106387C (pl)
AR (1) AR008875A1 (pl)
AT (1) ATE236884T1 (pl)
AU (1) AU719561B2 (pl)
BG (1) BG64278B1 (pl)
BR (1) BR9712256B1 (pl)
CA (1) CA2267322C (pl)
CY (1) CY2380B1 (pl)
CZ (1) CZ297474B6 (pl)
DE (1) DE69720757T2 (pl)
DK (1) DK0934280T3 (pl)
EE (1) EE03825B1 (pl)
ES (1) ES2196308T3 (pl)
HU (1) HU225158B1 (pl)
IL (2) IL129298A0 (pl)
MY (1) MY116980A (pl)
NO (1) NO312960B1 (pl)
NZ (1) NZ334971A (pl)
PL (1) PL194673B1 (pl)
PT (1) PT934280E (pl)
RU (1) RU2180902C2 (pl)
SI (1) SI0934280T1 (pl)
SK (1) SK285878B6 (pl)
TR (1) TR199900732T2 (pl)
UA (1) UA62939C2 (pl)
WO (1) WO1998014432A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068194B1 (en) 1998-04-01 2003-11-05 Janssen Pharmaceutica N.V. Pde iv inhibiting pyridine derivatives
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7476688B2 (en) * 2001-04-19 2009-01-13 Eisai R&D Management Co., Ltd. Cyclic amidine derivatives
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
EP1410795B1 (en) * 2001-07-11 2009-10-14 Nikken Chemicals Company, Limited Remedies for allergic eye diseases
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
KR20040075004A (ko) 2001-12-14 2004-08-26 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 비폴리펩티드 고리에이엠피 레벨 모듈레이터를 이용한배란 유도 방법
EP1602646A4 (en) * 2003-02-19 2010-07-28 Eisai R&D Man Co Ltd PROCESS FOR PREPARING CYCLIC BENZAMIDINE DERIVATIVES
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス,インコーポレイティド 神経発生のgaba受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013184755A2 (en) * 2012-06-07 2013-12-12 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
GB2533925A (en) * 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784461B2 (ja) * 1986-12-19 1995-09-13 日本バイエルアグロケム株式会社 殺虫性ニトロイミノ又はシアノイミノ化合物
JPH05310650A (ja) * 1991-08-22 1993-11-22 Nippon Soda Co Ltd 新規なアミン誘導体、その製造方法及び殺虫剤
EP0652868B1 (en) * 1992-07-28 2004-11-10 Aventis Pharma Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE
ATE234270T1 (de) * 1992-12-02 2003-03-15 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
AU7267094A (en) * 1993-07-28 1995-02-28 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
WO1995005386A1 (en) * 1993-08-19 1995-02-23 Smithkline Beecham Corporation Phenethylamine compounds
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
ATE217865T1 (de) * 1994-06-24 2002-06-15 Euro Celtique Sa Verbindungen zur hemmung von phosphodiesrerase iv
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
TW375612B (en) * 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
DE69720757D1 (de) 2003-05-15
SI0934280T1 (en) 2003-12-31
BG64278B1 (bg) 2004-08-31
IL129298A (en) 2006-04-10
NZ334971A (en) 2000-09-29
BG103220A (en) 1999-11-30
SK34499A3 (en) 2000-04-10
EE9900112A (et) 1999-10-15
CA2267322C (en) 2007-11-06
PT934280E (pt) 2003-08-29
AR008875A1 (es) 2000-02-23
ES2196308T3 (es) 2003-12-16
CY2380B1 (en) 2004-06-04
CA2267322A1 (en) 1998-04-09
CZ102899A3 (cs) 1999-07-14
NO312960B1 (no) 2002-07-22
CZ297474B6 (cs) 2006-12-13
KR20000029964A (ko) 2000-05-25
TR199900732T2 (xx) 1999-08-23
DE69720757T2 (de) 2004-03-04
EE03825B1 (et) 2002-08-15
SK285878B6 (sk) 2007-10-04
JP2000503678A (ja) 2000-03-28
NO991560D0 (no) 1999-03-30
ATE236884T1 (de) 2003-04-15
CN1232456A (zh) 1999-10-20
RU2180902C2 (ru) 2002-03-27
UA62939C2 (uk) 2004-01-15
WO1998014432A1 (en) 1998-04-09
HU225158B1 (en) 2006-07-28
HK1020344A1 (en) 2000-04-14
PL332573A1 (en) 1999-09-27
DK0934280T3 (da) 2003-07-21
BR9712256A (pt) 1999-08-24
NO991560L (no) 1999-06-02
CN1106387C (zh) 2003-04-23
EP0934280A1 (en) 1999-08-11
HUP9904063A2 (hu) 2000-09-28
US6051718A (en) 2000-04-18
HUP9904063A3 (en) 2000-11-28
AU719561B2 (en) 2000-05-11
KR100520002B1 (ko) 2005-10-13
AU4779297A (en) 1998-04-24
BR9712256B1 (pt) 2011-04-19
PL194673B1 (pl) 2007-06-29
EP0934280B1 (en) 2003-04-09
MY116980A (en) 2004-04-30
JP3068208B2 (ja) 2000-07-24

Similar Documents

Publication Publication Date Title
IL126951A0 (en) Carboline derivatives
ZA975543B (en) Phenylamino-substituted tricyclic derivatives
ZA972689B (en) 6-Phenylpyridyl-2-amine derivatives
ZA9710906B (en) 6-Phenylpyridyl-2-amine derivatives
IL125379A (en) 19-nor-pregnene derivatives
IL129298A0 (en) PDE iv inhibiting 2-cyanoiminoimidazole derivatives
ZA974053B (en) Alkylaminobenzothiazole and -benzoxazole derivatives
ZA978809B (en) PDE IV inhibiting 2-cyanoiminoimidazole derivatives
HUP9701835A3 (en) Vinyl-pirrolidinone-cephalosporin derivatives
IL129418A0 (en) 2-Methoxyphenylpiperazine derivatives
IL138745A0 (en) Pde iv inhibiting pyridine derivatives
IL125149A0 (en) Pyrazol-4-yl-hetaroyl derivatives
PL334558A1 (en) Cephalosporinic derivatives
HU9701479D0 (en) N-benzylazolium derivatives
GB9604996D0 (en) Benzodiazonine derivatives
GB9603226D0 (en) Heterocyclyl-ergoline derivatives
GB9600063D0 (en) Guaridine derivatives
ZA971911B (en) 2-thioxo-tetrahydropyrimidin-4-one derivatives
IL130283A0 (en) Polysaccharide-peptide derivatives
GB9702049D0 (en) Tetrahhydroisoquinoline derivatives
HU9601036D0 (en) Aryl-sulfonyl-hydroxamic-acid derivatives
GB9608592D0 (en) Imidazopyridine derivatives
IL145863A (en) Benzothiophenecarboxamide derivatives
GB9610888D0 (en) Aralkoxy-morphinan derivatives
ZA97172B (en) Heterocycle-condensed morphinoid derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed